

DAY 1 - 9 JANUARY 2026 - PLENARY SESSION HALL

Start	End	Topic
12:00	12:30	REGISTRATION
12:30	13:30	Welcome and Introduction
12:30	13:30	Prostate Cancer - Session 1
12:30	12:45	State of Art: Radiogenomics and natural history of visible vs invisible cancers: The case for image guided management of prostate cancer.
12:45	13:00	Advances in Imaging Techniques in Prostate Cancer: From Screening to Precision Detection
13:00	13:15	Uncovering the Truth About Prostate Biopsy in 2025
13:15	13:30	Prostate-Specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer
13:30	13:45	Group Case Discussion (Case-Based Panel): Management of Localized Prostate Cancer (Active Surveillance, Focal Therapy, Robotic-Assisted Surgery)
13:45	13:50	Q&A
13:50	14:55	Prostate Cancer - Session 2
13:50	14:05	Novel Guidelines for Metastatic Prostate Cancer: What Is Our Point of View in the Arab World?
14:05	14:20	Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
14:20	14:35	Focal therapy: Uses and missuses.
14:35	14:50	Video-Based Discussion: Challenging Cases in Robotic Prostatectomy
14:50	15:05	Group Case Discussion (Case-Based Panel): Low-Risk Prostate Cancer—Is There an Agreed Policy on Who to Treat?
15:05	15:10	Q&A
15:10	15:40	Afternoon Coffee Break
15:40	16:45	Prostate Cancer - Session 3
15:40	15:55	How Does PSMA Change Your Management vs Conventional Imaging?
15:55	16:10	Hormonal Therapy Beyond ADT: Current Standards and Future Directions
16:10	16:25	Changing Treatment Paradigms for Hormone-Naïve and Castration-Resistant Prostate Cancer
16:25	16:40	Group Case Discussion: Future Directions in Systemic Treatment of Metastatic Hormone-Sensitive Prostate Cancer
16:40	16:45	Q&A
16:45	17:45	Consensus Breakout Sessions

DAY 2 - 10 JANUARY 2026 - PLENARY SESSION HALL

Start	End	Topic
8:00	8:30	REGISTRATION
8:30	9:30	Renal Cell Carcinoma - Session 1
8:45	9:00	FDG PET/CT–Based Response Assessment in Renal Malignancies
9:00	9:15	WHO/ISUP Classification, Grading, and Pathological Staging of Renal Cell Carcinoma: Standards and Controversies
9:15	9:30	Off-Clamp Robotic Partial Nephrectomy: Points of Technique and Debate
9:30	9:40	Group Case Discussion: Perioperative Immunotherapy in Localized Renal Cell Carcinoma
9:40	9:45	Q&A
9:45	10:15	Morning Coffee Break
10:15	11:20	Renal Cell Carcinoma - Session 2
10:15	10:30	Non-Clear Cell RCC: Therapeutic Strategies
10:30	10:45	Debate: Cystic Renal Cell Carcinoma—Clinical Behavior and Management
10:45	11:00	Video-Based Discussion: Renorrhaphy Techniques for Partial Nephrectomy (Refining Technique)
11:00	11:10	Group Case Discussion: High-Risk Localized RCC After Surgery—Should We Start Neoadjuvant Therapy?
11:10	11:15	Q&A
11:15	12:20	Renal Cell Carcinoma - Session 3
11:15	11:30	The Role of AI in Pathology and Digital RCC Grading
11:30	11:45	Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma: An Update
11:45	12:00	Laparoscopic Partial Nephrectomy: Rest in Peace? Point of View of a Robotic Surgeon
12:00	12:15	Group Case Discussion: Comprehensive Whole-Course Management Strategy for Recurrent Renal Cell Carcinoma
12:15	12:20	Q&A
12:20	13:20	Lunch Break
13:20	14:25	Bladder Cancer Innovations & Challenges - Session 1
13:20	13:35	Liquid Biopsies: Leading the Future of Cancer Early Detection
13:35	13:50	From Papillary to CIS: Tailoring NMIBC Treatment
13:50	14:05	Therapeutic Advances in Bladder Preservation for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
14:05	14:20	Video-Based Discussion: En Bloc Laser Resection of Superficial Bladder Cancer—Standardization and Evaluation
14:20	14:35	Group Case Discussion: Is BCG Still the Best Option for NMIBC in 2025?
14:35	14:40	Q&A
14:40	15:10	Afternoon Coffee Break
14:40	15:45	Bladder Cancer Innovations & Challenges - Session 2
14:40	14:55	Urine Biomarkers in Bladder Cancer—Current Status and Future Perspectives
14:55	15:10	Multidisciplinary Guidelines for Diagnosis and Treatment of MIBC
15:10	15:25	How Neoadjuvant Chemotherapy Improves Survival in MIBC: Point of Debate
15:25	15:40	Group Case Discussion: Management of Muscle-Invasive Bladder Cancer (MIBC) (Cystectomy vs Trimodality Therapy vs Alternatives)
15:40	15:45	Q&A
15:45	16:50	Bladder Cancer Innovations & Challenges - Session 3
15:45	16:00	Advanced/Metastatic Bladder Cancer: Current Status and Future Directions
16:00	16:15	Role of Surgery in Locally Advanced/Metastatic Urothelial Tumor: Rapidly Changing Treatment Landscape
16:15	16:30	Targeted Therapies in the Management of Metastatic Bladder Cancer
16:30	17:00	Radical Cystectomy Club (RCC): Open vs Robotic vs Single-Port Robotic—6 Minutes Each, Then Cross Swords for Another 4 Minutes
17:00	17:05	Q&A
17:05	17:35	Closing Plenary & Readouts

Program subject to change



Congress Secretariat: MCI Middle East



+971 4 311 6300



www.aauoncologysummit.com